 |
市场调查报告书
商品编码
1357962
斯塔加特氏症药物市场：依药物类型、年龄层、配销通路、地区Stargardt Disease Therapeuticss Market, By Drug Type (Emixustat, LBS-008, others, By Age Group (Children and Adult ), By Distribution Channel, and By Region |
||||||
预计2023年Stargardt病药物的全球市场规模为2.135亿美元，预测期内（2023-2030年）年复合成长率为31.7%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2022年 | 2023年市场规模 | 2.135 亿美元 |
| 实绩资料 | 2018-2021 | 预测期 | 2023-2030 |
| 预测期年复合成长率 | 31.70% | 2030年市场规模预测 | 14.672 亿美元 |
Stargardt症是一种由单一基因的细微变化引起的遗传疾病。也称为眼底黄斑，是黄斑部营养不良最常见的形式。比例万分之一的人会发生这种情况，男性和女性罹患。 Stargard 会导致称为黄斑部的视网膜中央部分恶化。该区域最终将被一圈白色或黄色斑点包围。视网膜色素上皮 (RPE) 是视网膜的重要层，也会受到称为脂褐质的「废物」产物积聚的影响。诊断出患有斯塔加特氏症可能很困难，但只要有正确的资讯和支持，您就可以应付。重要的是要记住，在大多数情况下，患有斯塔加特病的人不会完全丧失视力。 Stargardt 病通常只影响中央视力。週边视力通常不受影响。目前正在进行大量针对潜在治疗方法的研究。因此，此类先进治疗方法的引入预计将在预测期内推动全球 Stargardt 疾病治疗市场的成长。
市场动态
医疗设备业的主要参与者致力于为各种患有史塔加特病的患者群开发治疗方法。因此，将此类先进药物引入市场预计将在预测期内推动全球 Stargardt 疾病治疗市场的成长。例如，2023年6月5日，生物製药公司Archius Pharmaceuticals宣布推出一种潜在的缓解疾病，用于治疗Stargardt病，这是导致儿童和青少年失明的主要遗传原因，并宣布已筹集1.5亿美元B轮资金筹措支持精准医疗产品视网醇（ALK-001）的註册和上市。资金筹措由 Bain Capital Lifesciences主导，TCGX、Wellington Management 和 Sofinova Investments 也参与其中。
本研究的主要特点
- 该报告对全球Stargardt疾病治疗市场进行了详细分析，并提供了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率(CAGR)。它还揭示了各个细分市场的潜在商机，并说明了市场有吸引力的投资提案矩阵。
- 它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
- 它根据公司亮点、产品系列、主要亮点、业绩和策略等参数，介绍了全球 Stargardt 疾病治疗市场的主要企业。
- 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
- 全球 Stargardt 疾病治疗药物市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
- 透过用于分析全球 Stargardt 疾病治疗药物市场的各种策略矩阵，将有助于相关人员做出决策。
目录
第1章调查目的和假设
- 这项研究的目的
- 假设
- 简称
第2章市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第3章市场动态、法规及趋势分析
- 市场动态
- 促进因素
- 抑制因素
- 市场机会
- 影响分析
- 最近测试启动
- 流行病学
- 合併、收购和合作
- 法规场景
- 主要进展
- PEST分析
- 流行病学
第4章全球Stargardt疾病治疗药物市场-新型冠状病毒感染疾病（COVID-19）的影响分析
- 经济影响
- 新型冠状病毒感染疾病（COVID-19）的流行病学
- 对需求和供给的影响
第5章全球斯塔加特病药物市场：按药物类型，2018-2030
- Emixustat
- LBS-008
- 其他（Gildeuretinol）
第6章全球斯塔加特氏症药物市场：依年龄组别，2018-2030
- 儿童（17岁以下）
- 成人（17岁以上）
第7章全球斯塔加特氏症药物市场：依配销通路划分，2018-2030
- 医院药房
- 零售药房
- 网路药房
第8章全球斯塔加特病药物市场：按地区划分，2018-2030
- 北美洲
- 美国
- 加拿大
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中东
- GCC
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第9章竞争形势
- 公司简介
- Kubota Pharmaceutical Holdings Co., Ltd.
- Stargazer Pharmaceuticals Inc.
- Iveric Bio, Inc.
- Sanofi SA
- Alkeus Pharmaceuticals Inc.
- Astellas Pharma Inc.
- CHABiotech CO., Ltd
- ReVision Therapeutics, Inc.
- Lin BioScience, Inc.
- Biogen Inc.
- F.Hoffmann-La Roche AG
- Ocugen, Inc.
- Ascidian Therapeutics
- Nanoscope Therapeutics Inc.
- Aequus Pharmaceuticals Inc.
- Fera Pharmaceuticals, LLC
- Insmed Incorporated
- Belite Bio, Inc.
- SpliceBio
第10章章
- 参考
- 调查方法
Global stargardt disease therapeutics market is estimated to be valued at US$ 213.5 Mn in 2023, and is expected to exhibit a CAGR of 31.7% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 213.5 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 31.70% | 2030 Value Projection: | US$ 1,467.2 Mn |
Stargardt disease is a genetic condition that is caused by a tiny alteration in a single gene. It is also known as fundus flavimaculatus, and is the most common form of macular dystrophy. It affects approximately one in 10,000 people and affects both males and females. Stargardt causes a wasting of a central area of the retina called the macula. This area is eventually surrounded by a ring of white or yellow spots. An important layer of the retina, the retinal pigment epithelium (RPE), is also affected by an accumulation of 'waste' material called lipofuscin. Being diagnosed with Stargardt disease can be distressing, but with the right information and support, people can cope very well. It is important to remember that in the vast majority of cases, patients with stargardt disease do not lose all their sight. Stargardt disease usually affects central vision only. Peripheral vision is not usually affected. There is a great deal of research going on into potential treatments. Thus, introduction of such advanced treatment options in the market is expected to drive global stargardt disease therapeutics market growth over the forecast period.
Market Dynamics
The key players in the medical devices industry are focusing on the development of therapeutic drugs for various patient pool suffering from Stargardt disease. Thus, introduction of such advanced drugs in the market is expected to drive growth of the global stargardt disease therapeuticss market over the forecast period. For instance, on June 05, 2023, Alkeus Pharmaceuticals, a biopharmaceutical company, announced that the company had raised a US$ 150 million in Series B financing to support the registration and launch of gildeuretinol (ALK-001), a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness in children and young adults. The financing was led by Bain Capital Life Sciences, with additional participation by TCGX, Wellington Management and Sofinnova Investments.
Key features of the study:
- This report provides an in-depth analysis of the global stargardt disease therapeuticss market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global stargardt disease therapeuticss market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd, ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., Hoffmann-La Roche AG, Ocugen, Inc., Ascidian Therapeutics, Nanoscope Therapeutics Inc., Aequus Pharmaceuticals Inc., Fera Pharmaceuticals, LLC, Insmed Incorporated, Belite Bio, Inc., and SpliceBio
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global stargardt disease therapeuticss market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global stargardt disease therapeuticss market
Detailed Segmentation:
- Global Stargardt Disease Therapeuticss Market, By Drug Type:
- Emixustat
- LBS-008
- Others (Gildeuretinol)
- Global Stargardt Disease Therapeutics Market, By Age Group:
- Children (Below 17 Years)
- Adult (Above 17 Years)
- Global Stargardt Disease Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Stargardt Disease Therapeutics Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Kubota Pharmaceutical Holdings Co., Ltd.
- Stargazer Pharmaceuticals Inc.
- Iveric Bio, Inc.
- Sanofi S.A.
- Alkeus Pharmaceuticals Inc.
- Astellas Pharma Inc.
- CHABiotech CO., Ltd
- ReVision Therapeutics, Inc
- Lin BioScience, Inc.
- Biogen Inc.
- Hoffmann-La Roche AG
- Ocugen, Inc.
- Ascidian Therapeutics
- Nanoscope Therapeutics Inc.
- Aequus Pharmaceuticals Inc.
- Fera Pharmaceuticals, LLC
- Insmed Incorporated
- Belite Bio, Inc.
- SpliceBio
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Age Group
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Epidemiology
4. Global Stargardt Disease Therapeutics Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Stargardt Disease Therapeutics Market, By Drug Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Emixustat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- LBS-008
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Others (Gildeuretinol)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
6. Global Stargardt Disease Therapeutics Market, By Age Group, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Children (Below 17 Years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Adult (Above 17 Years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
7. Global Stargardt Disease Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
8. Global Stargardt Disease Therapeutics Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Kubota Pharmaceutical Holdings Co., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Stargazer Pharmaceuticals Inc.
- Iveric Bio, Inc.
- Sanofi S.A.
- Alkeus Pharmaceuticals Inc.
- Astellas Pharma Inc.
- CHABiotech CO., Ltd
- ReVision Therapeutics, Inc.
- Lin BioScience, Inc.
- Biogen Inc.
- F.Hoffmann-La Roche AG
- Ocugen, Inc.
- Ascidian Therapeutics
- Nanoscope Therapeutics Inc.
- Aequus Pharmaceuticals Inc.
- Fera Pharmaceuticals, LLC
- Insmed Incorporated
- Belite Bio, Inc.
- SpliceBio
10. Section
- References
- Research Methodology
- About us and Sales Contact
